Holen Sie sich die Stockscreener-App
6.14
1.60%
-0.10
Vorhandelsmarkt:
6.12
-0.02
-0.33%
Certara Inc Aktie (CERT) Neueste Nachrichten
Certara (CERT) price target decreased by 23.74% to 9.63 - MSN
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight - GlobeNewswire Inc.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates - MSN
Certara to sell regulatory and medical writing business for up to $135M - MSN
How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations - Yahoo Finance
Certara strategic business divestiture comes at right time, says analyst - MSN
Wall Street analysts think Certara (CERT) could surge 43.28%: Read this before placing a bet - MSN
Certara: An Interesting Situation To Keep Track Off (NASDAQ:CERT) - Seeking Alpha
CERT Price Today: Certara, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
(CERT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst - Sahm
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report? - MSN
CERT Certara posts 8.8 percent year-over-year Q4 2025 revenue growth despite sizeable EPS miss pressuring shares.Barrier to Entry - UBND thành phố Hải Phòng
Certara to Divest Regulatory and Medical Writing Business - The Globe and Mail
Certara to sell regulatory writing unit to Veristat for $135M By Investing.com - Investing.com India
Is Certara (CERT) stock considered stable (+2.26%) 2026-04-22Price Surge - Cổng thông tin điện tử tỉnh Lào Cai
Certara (CERT) Sells Regulatory Writing Business for Up to $135 Million - GuruFocus
Veristat to Acquire Certara’s Regulatory and Medical Writing Business - Business Wire
Veristat, LLC signed a definitive agreement to acquire Regulatory and Medical Writing business of Certara, Inc for approximately $140 million. - marketscreener.com
Certara to Sell Regulatory and Medical Writing Business to Veristat for Up to $135 Million, Refocuses on Model-Informed Drug Development 1 - Minichart
Certara to sell regulatory writing unit to Veristat for $135M - Investing.com
Certara to Sell Regulatory, Medical Writing Business to Veristat for $135 Million - marketscreener.com
Certara : Regulatory and Medical Writing – Supplemental Information - marketscreener.com
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat - The Manila Times
Certara to Sell Global Medical Writing Business to Veristat for $100M, Plus Up to $35M Earn-Out - TradingView
Certara (NASDAQ: CERT) divests regulatory and medical writing unit to Veristat - Stock Titan
Certara, Inc. $CERT Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Why Certara (CERT) Stock Is Rising Now (Investor Interest) 2026-04-16Pro Trader Recommendations - Cổng thông tin điện tử Tỉnh Sơn La
Certara Inc stock (US1567671046): Why does its biosimulation edge matter more now for drug developme - AD HOC NEWS
Liquidity Mapping Around (CERT) Price Events - Stock Traders Daily
CERT Maintained by Keybanc -- Price Target Lowered to $8.00 - GuruFocus
Portfolio Update: How do insiders feel about Certara Inc2026 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
KeyBanc Maintains Certara(CERT.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Certara (NASDAQ:CERT) Price Target Cut to $8.00 by Analysts at KeyCorp - MarketBeat
Bioequivalence Studies Simulators Market is expected to Hit US$ - openPR.com
Craig-Hallum Maintains Certara(CERT.US) With Hold Rating - Moomoo
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026 - The Manila Times
Certara sets May 11 earnings release, webcast starts at 8:30 ET - Stock Titan
If You Invested $1,000 in Certara, Inc. (CERT) - Stock Titan
How The Certara (CERT) Story Is Evolving As Price Targets Reset And Growth Plans Lag - Yahoo Finance
4.08%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):